Gyre Therapeutics (GYRE) Finished Goods (2022 - 2026)

Gyre Therapeutics (GYRE) has reported Finished Goods for 5 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Finished Goods rose 27.55% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (up 27.55% YoY), while the FY2025 annual figure was $2.9 million, up 10.71% from the prior year.
• Finished Goods grew to $4.2 million in Q1 2026 per GYRE's latest filing, from $2.9 million in the prior quarter.
• Across five years, Finished Goods topped out at $4.2 million in Q1 2026 and bottomed at $1.4 million in Q4 2023.
• Historically, Finished Goods has averaged $2.5 million across 5 years, with a median of $2.6 million in 2024.
• Annual changes were most pronounced in 2023 — Finished Goods slipped 2.43% — and 2025, when it surged 122.77%.
• Gyre Therapeutics' Finished Goods stood at $1.4 million in 2022, then dropped by 2.43% to $1.4 million in 2023, then jumped by 91.5% to $2.6 million in 2024, then climbed by 10.71% to $2.9 million in 2025, then soared by 44.61% to $4.2 million in 2026.
• Business Quant data shows GYRE's Finished Goods at $4.2 million in Q1 2026, $2.9 million in Q4 2025, and $3.3 million in Q3 2025.